FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:343-347 August 10, 1995 Number 6 Next

Abstract PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The ₃-adrenergic receptor is expressed in visceral adipose tissue and is thought to contribute to the regulation of the resting metabolic rate and lipolysis.

Methods To investigate whether mutations in the gene for the ₃-adrenergic receptor predispose patients to obesity and non-insulin-dependent diabetes mellitus (NIDDM), we studied this gene in 10 Pima Indians by analysis of single-stranded conformational polymorphisms and dideoxy sequence analysis. Association studies were performed in 642 Pima subjects (390 with NIDDM and 252 without NIDDM).

Results A missense mutation was identified in the gene for the ₃-adrenergic receptor that results in the replacement of tryptophan by arginine (Trp64Arg) in the first intracellular loop of the receptor. This mutation was detected with allelic frequencies of 0.31 in Pima Indians, 0.13 in 62 Mexican Americans, 0.12 in 49 blacks, and 0.08 in 48 whites in the United States. Among Pimas, the frequency of the Trp64Arg mutation was similar in nondiabetic and diabetic subjects. However, in subjects homozygous for the mutation the mean (±SD) age at the onset of NIDDM was significantly lower (36±10 years) than in Trp64Arg heterozygotes (40±10 years) or normal homozygotes (41±11 years; P = 0.02). Furthermore, subjects with the mutation tended to have a lower adjusted resting metabolic rate (P = 0.14 by analysis of covariance).

Conclusions Pima subjects homozygous for the Trp64Arg ₃-adrenergic–receptor mutation have an earlier onset of NIDDM and tend to have a lower resting metabolic rate. This mutation may accelerate the onset of NIDDM by altering the balance of energy metabolism in visceral adipose tissue.

Obesity is a known risk factor for the development of NIDDM^5,6 and, like NIDDM, has clear genetic determinants.^7,8 In humans, resting metabolic rate is a familial trait,^9,10 and a low resting metabolic rate is a risk factor for weight gain and obesity.^11,12 In rodents, resting metabolic rate is regulated by the sympathetic nervous system and acts through the modulation of lipolysis and thermogenesis in brown adipose tissue.^13,14 Although adult humans do not have anatomically distinct deposits of brown adipose tissue, the identification of uncoupling protein, a marker widely regarded as specific for such tissue, suggests that modulation of thermogenesis may also be important in human adipose tissue.¹⁵

The ₃-adrenergic receptor crosses the cell membrane seven times, is coupled to guanine-nucleotide–binding (G) proteins, and is localized in adipose tissue. Stimulation of the receptor by -adrenergic agonists activates adenylate cyclase, which increases intracellular concentrations of cyclic AMP (cAMP) and results in increased lipolysis and thermogenesis.^16,17,18 There is evidence that molecular abnormalities in the ₃-adrenergic receptor may lead to obesity and NIDDM. Expression of the receptor is markedly decreased in rodent models of obesity^19,20; mice with knockout (disruption) of the gene for the receptor have marked reductions in lipolysis stimulated by -agonists,²¹ and ₃-specific agonists have potent antiobesity and antidiabetic effects in both animals^22,23 and humans.^23,24 To examine further the potential role of inherited defects in this gene as contributors to obesity and NIDDM, we evaluated a group of Pima Indians, an ethnic group with a very high prevalence of these disorders, for the presence of mutations in the ₃-adrenergic–receptor gene.

Methods

Study Subjects

All protocols were approved by the ethics committees of the National Institute of Diabetes and Digestive and Kidney Diseases, the Indian Health Service, and the tribal council of the Gila River Indian Community and were performed after written informed consent was obtained from the subjects. The 642 subjects (390 with NIDDM and 252 without NIDDM) who participated in the main study were full-blooded Pima or Tohono O'odham Indians (or a mixture of these two closely related tribes) 35 to 87 years of age. The selection of subjects was not based on their familial relationship to any other subject or to the presence of diabetes. NIDDM was diagnosed on the basis of the classification system of the World Health Organization.²⁵ Anthropometric measurements and measurements of body composition were made by standard methods.²⁶ The relations among the ₃-adrenergic–receptor genotype, the resting metabolic rate (which was measured by indirect calorimetry with the subject in a respiratory chamber), plasma concentrations of glucose and insulin after oral glucose administration, and sensitivity to insulin (as determined by the hyperinsulinemic–euglycemic clamp technique) were studied in a separate group of 210 nondiabetic Pima Indians.^9,26 For the estimation of allelic frequencies, ₃-adrenergic–receptor genotypes were also determined in 62 Mexican Americans from San Antonio, Texas,²⁷ and in 49 blacks and 48 whites from the Baltimore metropolitan area.

Analysis of Single-Stranded Conformational Polymorphisms of the ₃-Adrenergic–Receptor Gene

Genomic DNA was prepared from leukocytes or immortalized cell lines by established methods. Genomic DNA was amplified by the polymerase chain reaction (PCR) as described elsewhere.²⁸ Ten pairs of primers were used to generate 10 overlapping PCR products encompassing the entire coding region, the 5' untranslated region, the exon–intron splice junctions, and 521 base pairs (bp) of the regulatory region of the ₃-adrenergic–receptor gene^17,20,29 (and data deposited with the National Auxiliary Publications Service, ^*). For the analysis of single-stranded conformational polymorphisms, the PCR products were radiolabeled by the addition of [-³²P]deoxycytidine triphosphate to the reaction mixture. Denatured PCR products were loaded onto a polyacrylamide gel (MDE, AT Biochemicals, Malvern, Pa.), and subjected to electrophoresis at 4 to 6 W for 18 to 20 hours under four gel conditions: with and without 10 percent glycerol at 4°C and at 25°C.³⁰ The gel was vacuum-dried, and autoradiography was performed.

Dideoxy Sequence Analysis

Variants detected by analysis of single-stranded conformational polymorphisms were subjected to direct dideoxy sequence analysis with asymmetric PCR²⁸ and Sequenase Version 2.0 kits (United States Biochemicals, Cleveland). Changes in bases were confirmed by the sequencing of the opposite strands and by digestion with restriction enzymes.

Detection of the Mutated Receptor by Hybridization with Allele-Specific Oligonucleotides

A 367-bp fragment of the ₃-adrenergic–receptor gene encompassing the mutation site was amplified by PCR with primers 5'TTCCTTCTTTCCCTACCGCCC3' and 5'GCAGCCAGTGGCGCCCAACGG3'. The PCR products were blotted in duplicate onto nylon membranes. Hybridization was accomplished with ³²P-radiolabeled oligonucleotides corresponding to either the normal sequence of the ₃-adrenergic–receptor gene (5'CATCGCCTGGACTCCGA3'; the probe for Trp64) or the sequence of the Trp64Arg ₃-adrenergic–receptor gene (5'CATCGCCCGGACTCCGA3'; the probe for Arg64).³¹ The membranes were then washed twice in 2x sodium chloride–sodium phosphate–EDTA (SSPE) (1x SSPE is 150 mM sodium chloride, 10 mM sodium phosphate, and 1.25 mM EDTA; pH 7.4) and 0.05 percent sodium dodecyl sulfate at 60°C (the Trp64 probe) or 62°C (the Arg64 probe) for 15 minutes, and autoradiography was performed.

Statistical Analysis

In the studies of the association of variables with genotype, chi-square tests were performed. In the analysis of quantitative traits, an analysis of variance was used and, where appropriate, covariates were included in the models.

Results

Analysis of Single-Stranded Conformational Polymorphisms

Ten Pima Indians with obesity and NIDDM, none of whom were first-degree relatives of each other, were initially screened for variation in the ₃-adrenergic–receptor gene. Analysis of single-stranded conformational polymorphisms revealed two variant patterns in the coding region. Dideoxy sequence analysis of one variant (present in 2 of the 10 Pimas) revealed a silent replacement of cytosine (C) by thymidine (T) at nucleotide position 381 (codon 127; i.e., ACC^ThrACT^Thr). Sequence analysis of the second variant (present in 5 of the 10 Pimas) revealed a heterozygous pattern with a replacement of thymidine (T) by cytosine (C) at nucleotide position 190 (Figure 1A and Figure 1B). This change in bases predicted a replacement of tryptophan (TGG) by arginine (CGG) at position 64 (Trp64Arg), an amino acid in the first of the three intracellular loops of the receptor (Figure 2). This change in bases was confirmed by restriction-enzyme digestion with BstNI (Figure 3A and Figure 3B). To screen for mutations that may have been missed in the analysis of single-stranded conformational polymorphisms, the entire coding region of the ₃-adrenergic–receptor gene was sequenced in two additional Pima Indians with NIDDM. No new base changes were identified.

View larger version (17K): [in this window] [in a new window]   Figure 1. Identification of the Trp64Arg Mutation of the 3-Adrenergic–Receptor Gene. Panel A shows an autoradiograph of an analysis of conformational polymorphisms in a single strand of DNA from a region of the 3-adrenergic–receptor gene in 7 of 10 diabetic Pima Indians. The arrow shows a variant pattern in lanes 2 through 6. Panel B shows autoradiographs obtained by direct sequence analysis of a region of the gene, with the normal sequence on the left. The sequencing of one of the PCR products that revealed a variant pattern in Panel A showed both a thymidine (T) and a cytosine (C) at nucleotide position 190. The patient with this pattern was therefore heterozygous for the nucleotide substitution that alters the predicted sequence of amino acids at codon 64, causing a replacement of tryptophan by arginine (TGGCGG, or Trp64Arg).

 

View larger version (4K): [in this window] [in a new window]   Figure 2. Diagram of the 3-Adrenergic Receptor. Each amino acid is shown as a circle. The Trp64Arg mutation appears at the beginning of the first intracellular loop.

 

View larger version (6K): [in this window] [in a new window]   Figure 3. Use of Restriction-Enzyme Digestion to Confirm the Presence of the Trp64Arg Mutation. Panel A shows a restriction map of the 367-bp PCR product used for digestion with BstNI. Digestion of the normal sequence yields fragments of 15, 34, 61, 66, 94, and 97 bp in length, whereas the Trp64Arg mutation eliminates one of the BstNI sites (dashed line), yielding a novel 158-bp product. Panel B shows an ethidium bromide–stained gel after the digestion of two DNA samples with BstNI. One subject was heterozygous for the Trp64Arg mutation of the 3-adrenergic–receptor gene (Trp/Arg), and the other was homozygous for the normal receptor (Trp/Trp). As predicted, the mutation eradicated one of the five BstNI sites in the normal sequence, causing a 158-bp product that is not normally present to appear.

 
Allelic Frequencies of the Trp64Arg Mutation in Pima Indians and Other Subjects

Genomic DNA from 642 Pima Indians (390 subjects with NIDDM and 252 without NIDDM) was subjected to genotyping for the Trp64Arg missense mutation in the ₃-adrenergic receptor by hybridization with allele-specific oligonucleotides (Figure 4). The frequency of the Trp64Arg allele was 0.31. Nine percent of the subjects were homozygous for the mutation, 45 percent were heterozygous, and 46 percent lacked the mutation. When the genotypes were analyzed according to the subjects' age and sex, there was a statistically significant underrepresentation of Trp64Arg homozygotes among men 45 or older (P = 0.02) (Table 1).

View larger version (26K): [in this window] [in a new window]   Figure 4. Detection of Mutated and Normal 3-Adrenergic Receptors by Hybridization with Allele-Specific Oligonucleotides. The 367-bp PCR products encompassing the Trp64Arg mutation in five Pima Indians were subjected to slot blot analysis in duplicate with oligonucleotide probes that specifically recognize either the normal 3-adrenergic receptor (the Trp64 probe) or the mutation (the Arg64 probe), and autoradiography was performed. Normal homozygotes (Trp/Trp), heterozygotes (Trp/Arg), and Trp64Arg homozygotes (Arg/Arg) could be detected rapidly with this assay.

 

View this table: [in this window] [in a new window]   Table 1. Frequency of Homozygosity for the Trp64Arg Mutation of the b3-Adrenergic–Receptor Gene among the Pima Indians Studied, According to Age.

 
The frequency of the Trp64Arg allele among the 62 Mexican Americans (with 124 alleles) was 0.13. Among the 49 blacks (with 98 alleles) it was 0.12, and among the 48 whites (with 96 alleles) it was 0.08.

The Trp64Arg Genotype, NIDDM, and Obesity

Diabetes was not significantly associated with the Trp64Arg genotype in the 642 Pima Indians; the prevalence of NIDDM was 72 percent, 60 percent, and 60 percent, respectively, among Trp64Arg homozygotes, Trp64Arg heterozygotes, and normal homozygotes (P = 0.19). From these data we concluded that the prevalence of NIDDM was slightly but not significantly higher among Trp64Arg homozygotes than among the Pima subjects with the other two genotypes (prevalence-rate ratio, 1.2; 95 percent confidence interval, 1.0 to 1.5). The mean age of the Trp64Arg homozygotes at the onset of NIDDM was significantly lower than that of the heterozygotes and the normal homozygotes (P = 0.02) (Table 2). In view of this finding, we also examined the prevalence of diabetes that was diagnosed before the age of 25 years. Overall, this prevalence did not differ significantly between the three groups (P = 0.11), although our data showed that the prevalence of diabetes diagnosed before the age of 25 years was higher among Trp64Arg homozygotes than among subjects with either of the other two genotypes (prevalence-rate ratio, 2.7; 95 percent confidence interval, 1.1 to 6.8).

View this table: [in this window] [in a new window]   Table 2. Characteristics of 642 Pima Indians According to Genotype of the b3-Adrenergic Receptor.

 
There was a trend toward a higher mean (±SD) body-mass index (the weight in kilograms divided by the square of the height in meters) among the subjects homozygous for the Trp64Arg mutation (35.2±8.0) than among subjects heterozygous for the mutation (34.1±7.9) or the normal homozygotes (33.9±7.5) (Table 2). Although this trend persisted after adjustment for age and sex, the differences were not statistically significant; nor were there significant differences in the ratio of the waist to the hip circumference.

The Trp64Arg Mutation and the Resting Metabolic Rate

When we studied the separate group of 210 Pima Indians, we found a trend toward a lower resting metabolic rate in subjects with the Trp64Arg mutation of the ₃-adrenergic receptor (Table 2). After we adjusted for known covariates of the resting metabolic rate (fat-free mass, fat mass, and sex), the 22 subjects homozygous for the mutation expended an average of 82 kcal per day less than the 82 normal homozygotes; in the 106 heterozygotes, the average resting metabolic rate (36 kcal per day less than that of the normal homozygotes) was intermediate between the values for the two other groups (P = 0.14 by analysis of covariance). There were no significant associations of genotype with plasma concentrations of glucose or insulin during an oral glucose-tolerance test or with sensitivity to insulin as measured by the hyperinsulinemic–euglycemic clamp technique in this group.

Discussion

We have identified a mutation in the ₃-adrenergic–receptor gene that, although not in itself associated with NIDDM, was associated with the onset of NIDDM at an earlier age among Pima Indians homozygous for the mutation. This finding suggests that the mutation is not a major determinant of NIDDM in these subjects, but rather acts to accelerate the course of the disease. The underrepresentation in the study sample of men 45 or older who were homozygous for the mutation may indicate early mortality, perhaps due to the long-term complications of diabetes that would be expected if the disease had an earlier onset.

Very small decrements in the resting metabolic rate can lead to excess accumulation of energy, weight gain, and obesity. In prospective studies of adult Pima Indians, a small daily difference in the metabolic rate (70 kcal) was a risk factor for weight gain and obesity.¹² Indeed, subjects with the Trp64Arg mutation in the gene for the ₃-adrenergic receptor tended to have lower resting metabolic rates but were no more obese than normal subjects. Prospective measures of weight gain in younger subjects and association studies in subjects less genetically predisposed to obesity will be needed to define further the influence of this mutation on low energy expenditure and the development of obesity and NIDDM. Indeed, data from Widén and Clément and their colleagues,^32,33 in addition to our own studies of Mexican Americans (unpublished data), implicate this mutation, even in its heterozygous form, as a contributor to central obesity and weight gain, as well as to insulin resistance and NIDDM with an accelerated onset. These studies provide additional evidence that this missense mutation contributes to the genetic basis of the common forms of obesity, insulin resistance, and NIDDM.

The Trp64Arg mutation appears at the beginning of the first intracellular loop of the ₃-adrenergic receptor (Figure 2). On the basis of studies of the related ₂-adrenergic receptor³⁴ and rhodopsin,³⁵ the first intracellular loop is thought to be important for the proper movement of the receptor to the cell surface and possibly also for its coupling to G proteins. Defective expression at the cell surface or impaired signaling may lead to decreased lipolysis and thermogenesis in visceral fat tissue that may contribute to central obesity, insulin resistance, and NIDDM.

Supported by a grant (NIA 5T32AG00120) from the National Institutes of Health and by grants from the Mallinckrodt Foundation (to Dr. Shuldiner), the American Federation of Aging Research (to Dr. Shuldiner), the Chesapeake Education and Research Trust (to Drs. Walston, Silver, Austin, and Shuldiner), the Robert Wood Johnson Foundation (to Dr. Austin), and the Hartford Foundation (to Drs. Walston and Austin). Dr. Walston was supported by a Pfizer–American Geriatrics Society postdoctoral fellowship.

We are indebted to Drs. John Burton and Philip Zieve for their support; to Drs. Reubin Andres, Terri Beaty, and Chahrzad Rafizadeh-Montrose for their advice and helpful comments; and to Mr. Keith Tanner and Ms. Amy Patterson for their assistance.

^* See NAPS document no. 05233 for one page of supplementary material. To order, contact NAPS c/o Microfiche Publications, 248 Hempstead Tpk., West Hempstead, NY 11552.

Source Information

From the Divisions of Geriatric Medicine and Gerontology (J.W., F.S.C., S.A., J.R., A.R.S.) and Endocrinology and Metabolism (K.S.), Johns Hopkins University School of Medicine, Baltimore; the Clinical Diabetes and Nutrition Section (C.B.) and the Diabetes and Arthritis Epidemiology Section (W.C.K.), National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Ariz.; the Laboratory of Clinical Physiology, National Institute on Aging, Baltimore (F.S.C., J.D.S.); the Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Md. (N.R.); the Laboratoire d'Immunopharmacologie Moléculaire, Institut Cochin de Génétique Moléculaire, Paris (B.M., A.D.S.); and the Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center, San Antonio (M.P.S.).

Address reprint requests to Dr. Shuldiner at the Johns Hopkins University School of Medicine, 5501 Bayview Cir., Rm. 5A42, Baltimore, MD 21224.

References

1. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 1987;36:523-534. [Abstract]
2. Rotter JI, Vadheim CM, Rimoin DL. Genetics of diabetes mellitus. In: Rifkin H, Porte D Jr, eds. Ellenberg and Rifkin's diabetes mellitus: theory and practice. 4th ed. New York: Elsevier, 1990:378-413.
3. Elbein SC, Hoffman MD, Bragg KL, Mayorga RA. The genetics of NIDDM: an update. Diabetes Care 1994;17:1523-1533. [Medline]
4. Turner RC, Hattersley AT, Shaw JTE, Levy JC. Type II diabetes: clinical aspects of molecular biological studies. Diabetes 1995;44:1-10. [Abstract]
5. Barrett-Connor E. Epidemiology, obesity, and non-insulin-dependent diabetes mellitus. Epidemiol Rev 1989;11:172-181. [Free Full Text]
6. Knowler WC, Pettitt D, Saad M, et al. Obesity in the Pima Indians: its magnitude and relationship with diabetes. Am J Clin Nutr 1991;53:Suppl:1543S-1551S. [Free Full Text]
7. Bouchard C. Genetics of obesity and its prevention. World Rev Nutr Diet 1993;72:68-77. [Medline]
8. Stunkard AJ, Sørensen TIA, Hanis C, et al. An adoption study of human obesity. N Engl J Med 1986;314:193-198. [Abstract]
9. Bogardus C, Lillioja S, Ravussin E, et al. Familial dependence of the resting metabolic rate. N Engl J Med 1986;315:96-100. [Abstract]
10. Bouchard C, Tremblay A, Nadeau A, et al. Genetic effect in resting and exercise metabolic rates. Metabolism 1989;38:364-370. [CrossRef][Medline]
11. Ravussin E, Lillioja S, Knowler WC, et al. Reduced rate of energy expenditure as a risk factor for body-weight gain. N Engl J Med 1988;318:467-472. [Abstract]
12. Griffiths M, Payne PR, Stunkard AJ, Rivers JP, Cox M. Metabolic rate and physical development in children at risk of obesity. Lancet 1990;336:76-78. [CrossRef][Medline]
13. Rothwell NJ, Stock MJ. A role for brown adipose tissue in diet-induced thermogenesis. Nature 1979;281:31-35. [CrossRef][Medline]
14. Trayhurn P, Mercer SW. Brown adipose tissue thermogenesis in obese animals. Biochem Soc Trans 1986;14:236-239. [Medline]
15. Cassard AM, Bouillaud F, Mattei MG, et al. Human uncoupling protein gene: structure, comparison with rat gene, and assignment to the long arm of chromosome 4. J Cell Biochem 1990;43:255-264. [CrossRef][Medline]
16. Emorine LJ, Marullo S, Briend-Sutren M-M, et al. Molecular characterization of the human ₃-adrenergic receptor. Science 1989;245:1118-1121. [Free Full Text]
17. van Spronsen A, Nahmias C, Krief S, Briend-Sutren MM, Strosberg AD, Emorine LJ. The promoter and intron/exon structure of the human and mouse ₃-adrenergic-receptor genes. Eur J Biochem 1993;213:1117-1124. [Medline]
18. Krief S, Lönnqvist F, Raimbault S, et al. Tissue distribution of ₃-adrenergic receptor mRNA in man. J Clin Invest 1993;91:344-349.
19. Collins S, Daniel KW, Rohlfs EM, Ramkumar V, Taylor IL, Gettys TW. Impaired expression and functional activity of the ₃- and ₁-adrenergic receptors in adipose tissue of congenitally obese (C57BL/6J ob/ob) mice. Mol Endocrinol 1994;8:518-527. [Abstract]
20. Muzzin P, Revelli J-P, Kuhne F, et al. An adipose tissue-specific -adrenergic receptor: molecular cloning and down-regulation in obesity. J Biol Chem 1991;266:24053-24058. [Free Full Text]
21. Susulic S, Frederich RC, Lawitts JA, et al. Knockout of the ₃-adrenergic receptor gene. In: Program and abstracts of the 77th annual meeting of the Endocrine Society, June 14-17, 1995, Bethesda, Md.: Endocrine Society, 1995:36. abstract.
22. Himms-Hagen J, Cui J, Danforth E Jr, et al. Effect of CL-316,243, a thermogenic ₃-agonist, on energy balance and brown and white adipose tissues in rats. Am J Physiol 1994;266:R1371-R1382. [Free Full Text]
23. Connacher AA, Bennet WM, Jung RT. Clinical studies with the -adrenoreceptor agonist BRL 26830A. Am J Clin Nutr 1992;55:Suppl:258S-261S. [Free Full Text]
24. Mitchell TH, Ellis RD, Smith SA, Robb G, Cawthorne MA. Effects of BRL 35135, a -adrenoreceptor agonist with novel selectivity, on glucose tolerance and insulin sensitivity in obese subjects. Int J Obes 1989;13:757-766. [Medline]
25. Diabetes mellitus: report of a WHO study group. World Health Organ Tech Rep Ser 1985;727:7-113. 
26. Prochazka M, Lillioja S, Tait JF, et al. Linkage of chromosomal markers on 4q with a putative gene determining maximal insulin action in Pima Indians. Diabetes 1993;42:514-519. [Abstract]
27. Mitchell BD, Kammerer CM, Reinhart LJ, Stern MP. NIDDM in Mexican-American families: heterogeneity by age of onset. Diabetes Care 1994;17:567-573. [Abstract]
28. Shuldiner AR, Perfetti R. The polymerase chain reaction: applications to endocrine research. In: de Pablo F, Scanes CG, eds. Handbook of endocrine research techniques. San Diego, Calif.: Academic Press, 1993:457-86.
29. Liggett SB, Schwinn DA. Multiple potential regulatory elements in the 5' flanking region of the ₃-adrenergic receptor. DNA Seq 1992;2:61-63.
30. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874-879. [CrossRef][Medline]
31. Lyons J. Analysis of ras gene point mutations by PCR and oligonucleotide hybridization. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR protocols: a guide to methods and applications. San Diego, Calif.: Academic Press, 1990.
32. Widén E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association of a polymorphism in the ₃-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995;333:348-351. [Free Full Text]
33. Clément K, Vaisse C, Manning BSJ, et al. Genetic variation in the ₃-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 1995;333:352-354. [Free Full Text]
34. Ostrowski J, Kjelsberg MA, Caron MG, Lefkowitz RJ. Mutagenesis of the ₂-adrenergic receptor: how structure elucidates function. Annu Rev Pharmacol Toxicol 1992;32:167-183. [Medline]
35. Sung CH, Davenport CM, Nathans J. Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa: clustering of functional classes along the polypeptide chain. J Biol Chem 1993;268:26645-26649. [Free Full Text]

Abstract PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

This article has been cited by other articles:

• Pierola, J., Barcelo, A., de la Pena, M., Barbe, F., Soriano, J. B., Sanchez Armengol, A., Martinez, C., Agusti, A. (2007). {beta}3-Adrenergic receptor Trp64Arg polymorphism and increased body mass index in sleep apnoea. Eur Respir J 30: 743-747 [Abstract] [Full Text]  
• Marin, C., Perez-Jimenez, F., Gomez, P., Delgado, J., Paniagua, J. A., Lozano, A., Cortes, B., Jimenez-Gomez, Y., Gomez, M. J., Lopez-Miranda, J. (2005). The Ala54Thr polymorphism of the fatty acid-binding protein 2 gene is associated with a change in insulin sensitivity after a change in the type of dietary fat. Am. J. Clin. Nutr. 82: 196-200 [Abstract] [Full Text]  
• Masuo, K., Katsuya, T., Fu, Y., Rakugi, H., Ogihara, T., Tuck, M. L. (2005). Lys418Asn Polymorphism of the {alpha}2-Adrenoceptor Gene Relates to Serum Uric Acid Levels But Not to Insulin Sensitivity. Hypertension 46: 144-150 [Abstract] [Full Text]  
• Masuo, K., Katsuya, T., Fu, Y., Rakugi, H., Ogihara, T., Tuck, M. L. (2005). {beta}2- and {beta}3-Adrenergic Receptor Polymorphisms Are Related to the Onset of Weight Gain and Blood Pressure Elevation Over 5 Years. Circulation 111: 3429-3434 [Abstract] [Full Text]  
• Gomez, P., Perez-Jimenez, F., Marin, C., Moreno, J. A., Gomez, M. J., Bellido, C., Perez-Martinez, P., Fuentes, F., Paniagua, J. A., Lopez-Miranda, J. (2005). The -514 C/T polymorphism in the hepatic lipase gene promoter is associated with insulin sensitivity in a healthy young population. J Mol Endocrinol 34: 331-338 [Abstract] [Full Text]  
• Wang, X., Cui, Y., Tong, X., Ye, H., Li, S. (2004). Effects of the Trp64Arg Polymorphism in the {beta}3-Adrenergic Receptor Gene on Insulin Sensitivity in Small for Gestational Age Neonates. J. Clin. Endocrinol. Metab. 89: 4981-4985 [Abstract] [Full Text]  
• Romieu, I., Lazcano-Ponce, E., Sanchez-Zamorano, L. M., Willett, W., Hernandez-Avila, M. (2004). Carbohydrates and the Risk of Breast Cancer among Mexican Women. Cancer Epidemiol. Biomarkers Prev. 13: 1283-1289 [Abstract] [Full Text]  
• Kirstein, S. L., Insel, P. A. (2004). Autonomic Nervous System Pharmacogenomics: A Progress Report. Pharmacol. Rev. 56: 31-52 [Abstract] [Full Text]  
• McCole, S. D., Shuldiner, A. R., Brown, M. D., Moore, G. E., Ferrell, R. E., Wilund, K. R., Huberty, A., Douglass, L. W., Hagberg, J. M. (2004). {beta}2- and {beta}3-Adrenergic receptor polymorphisms and exercise hemodynamics in postmenopausal women. J. Appl. Physiol. 96: 526-530 [Abstract] [Full Text]  
• Matsushita, Y., Yokoyama, T., Yoshiike, N., Matsumura, Y., Date, C., Kawahara, K., Tanaka, H. (2003). The Trp64Arg Polymorphism of the {beta}3-Adrenergic Receptor Gene Is Not Associated with Body Weight or Body Mass Index in Japanese: A Longitudinal Analysis. J. Clin. Endocrinol. Metab. 88: 5914-5920 [Abstract] [Full Text]  
• Iwamoto, I., Fujino, T., Douchi, T., Nagata, Y. (2003). Association of Estrogen Receptor {alpha} and {beta}3-Adrenergic Receptor Polymorphisms With Endometrial Cancer. Obstet Gynecol 102: 506-511 [Abstract] [Full Text]  
• Korc, M. (2003). Diabetes Mellitus in the Era of Proteomics. Mol. Cell. Proteomics 2: 399-404 [Full Text]  
• Suzuki, N., Matsunaga, T., Nagasumi, K., Yamamura, T., Shihara, N., Moritani, T., Ue, H., Fukushima, M., Tamon, A., Seino, Y., Tsuda, K., Yasuda, K. (2003). {alpha}2B-Adrenergic Receptor Deletion Polymorphism Associates with Autonomic Nervous System Activity in Young Healthy Japanese. J. Clin. Endocrinol. Metab. 88: 1184-1187 [Abstract] [Full Text]  
• Tang, W., Stearns, R. A., Miller, R. R., Ngui, J. S., Mathvink, R. J., Weber, A. E., Kwei, G. Y., Strauss, J. R., Keohane, C. A., Doss, G. A., Chiu, S.-H. L., Baillie, T. A. (2002). Metabolism of a Thiazole Benzenesulfonamide Derivative, a Potent and Selective Agonist of the Human beta 3-Adrenergic Receptor, in Rats: Identification of a Novel Isethionic Acid Conjugate. Drug Metab. Dispos. 30: 778-787 [Abstract] [Full Text]  
• Mentuccia, D., Proietti-Pannunzi, L., Tanner, K., Bacci, V., Pollin, T. I., Poehlman, E. T., Shuldiner, A. R., Celi, F. S. (2002). Association Between a Novel Variant of the Human Type 2 Deiodinase Gene Thr92Ala and Insulin Resistance: Evidence of Interaction With the Trp64Arg Variant of the {beta}-3-Adrenergic Receptor. Diabetes 51: 880-883 [Abstract] [Full Text]  
• Oizumi, T., Daimon, M., Saitoh, T., Kameda, W., Yamaguchi, H., Ohnuma, H., Igarashi, M., Eguchi, H., Manaka, H., Tominaga, M., Kato, T. (2001). Genotype Arg/Arg, but not Trp/Arg, of the Trp64Arg Polymorphism of the {beta}3-Adrenergic Receptor Is Associated With Type 2 Diabetes and Obesity in a Large Japanese Sample. Diabetes Care 24: 1579-1583 [Abstract] [Full Text]  
• Guimaraes, S., Moura, D. (2001). Vascular Adrenoceptors: An Update. Pharmacol. Rev. 53: 319-356 [Abstract] [Full Text]  
• Susulic, V. S., LaVallette, L., Duzic, E., Chen, L., Shuey, D., Karathanasis, S. K., Steiner, K. E. (2001). Expression of the Human {beta}3-Adrenergic Receptor Gene in SK-N-MC Cells Is Under the Control of a Distal Enhancer. Endocrinology 142: 1935-1949 [Abstract] [Full Text]  
• Yamauchi, T., Kuno, T., Takada, H., Mishima, K., Nagura, Y., Takahashi, S., Kanmatsuse, K. (2001). The impact of Trp64Arg mutation in the {beta}3-adrenergic receptor gene on haemodialysis patients. Nephrol Dial Transplant 16: 641-642 [Full Text]  
• Barzilai, N., Shuldiner, A. R. (2001). Searching for Human Longevity Genes: The Future History of Gerontology in the Post-genomic Era. J. Gerontol. A Biol. Sci. Med. Sci. 56: 83M-87 [Abstract] [Full Text]  
• Sharma, A. M., Pischon, T., Hardt, S., Kunz, I., Luft, F. C. (2001). Hypothesis: {beta}-Adrenergic Receptor Blockers and Weight Gain : A Systematic Analysis. Hypertension 37: 250-254 [Abstract] [Full Text]  
• Dionne, I. J., Turner, A. N., Tchernof, A., Pollin, T. I., Avrithi, D., Gray, D., Shuldiner, A. R., Poehlman, E. T. (2001). Identification of an Interactive Effect of {beta}3- and {alpha}2b-Adrenoceptor Gene Polymorphisms on Fat Mass in Caucasian Women. Diabetes 50: 91-95 [Abstract] [Full Text]  
• Walston, J., Silver, K., Hilfiker, H., Andersen, R. E., Seibert, M., Beamer, B., Roth, J., Poehlman, E., Shuldiner, A. R. (2000). Insulin Response to Glucose Is Lower in Individuals Homozygous for the Arg 64 Variant of the {beta}-3-Adrenergic Receptor. J. Clin. Endocrinol. Metab. 85: 4019-4022 [Abstract] [Full Text]  
• Nadler, S. T., Stoehr, J. P., Schueler, K. L., Tanimoto, G., Yandell, B. S., Attie, A. D. (2000). The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc. Natl. Acad. Sci. USA 97: 11371-11376 [Abstract] [Full Text]  
• Urhammer, S. A., Hansen, T., Borch-Johnsen, K., Pedersen, O. (2000). Studies of the Synergistic Effect of the Trp/Arg64 Polymorphism of the {beta}3-Adrenergic Receptor Gene and the -3826 A->G Variant of the Uncoupling Protein-1 Gene on Features of Obesity and Insulin Resistance in a Population-Based Sample of 379 Young Danish Subjects. J. Clin. Endocrinol. Metab. 85: 3151-3154 [Abstract] [Full Text]  
• Hasegawa, Y., Fujii, K., Yamada, M., Igarashi, Y., Tachibana, K., Tanaka, T., Onigata, K., Nishi, Y., Kato, S., Hasegawa, T. (2000). Identification of Novel Human GH-1 Gene Polymorphisms that Are Associated with Growth Hormone Secretion and Height. J. Clin. Endocrinol. Metab. 85: 1290-1295 [Abstract] [Full Text]  
• Brodde, O.-E., Michel, M. C. (1999). Adrenergic and Muscarinic Receptors in the Human Heart. Pharmacol. Rev. 51: 651-690 [Abstract] [Full Text]  
• Büscher, R., Herrmann, V., Ring, K. M., Kailasam, M. T., O'Connor, D. T., Parmer, R. J., Insel, P. A. (1999). Variability in Phenylephrine Response and Essential Hypertension: A Search for Human alpha 1B-Adrenergic Receptor Polymorphisms. J. Pharmacol. Exp. Ther. 291: 793-798 [Abstract] [Full Text]  
• Carel, J. C., Le Stunff, C., Condamine, L., Mallet, E., Chaussain, J. L., Adnot, P., Garabédian, M., Bougnères, P. (1999). Resistance to the Lipolytic Action of Epinephrine: A New Feature of Protein Gs Deficiency. J. Clin. Endocrinol. Metab. 84: 4127-4131 [Abstract] [Full Text]  
• Heinonen, P., Koulu, M., Pesonen, U., Karvonen, M. K., Rissanen, A., Laakso, M., Valve, R., Uusitupa, M., Scheinin, M. (1999). Identification of a Three-Amino Acid Deletion in the {alpha}2B-Adrenergic Receptor That Is Associated with Reduced Basal Metabolic Rate in Obese Subjects. J. Clin. Endocrinol. Metab. 84: 2429-2433 [Abstract] [Full Text]  
• Bogardus, S. T. Jr, Concato, J., Feinstein, A. R. (1999). Clinical Epidemiological Quality in Molecular Genetic Research: The Need for Methodological Standards. JAMA 281: 1919-1926 [Abstract] [Full Text]  
• Shihara, N., Yasuda, K., Moritani, T., Ue, H., Adachi, T., Tanaka, H., Tsuda, K., Seino, Y. (1999). The Association between Trp64Arg Polymorphism of the {beta}3-Adrenergic Receptor and Autonomic Nervous System Activity. J. Clin. Endocrinol. Metab. 84: 1623-1627 [Abstract] [Full Text]  
• Festa, A., Krugluger, W., Shnawa, N., Hopmeier, P., Haffner, S. M., Schernthaner, G. (1999). Trp64Arg Polymorphism of the {beta}3-Adrenergic Receptor Gene in Pregnancy: Association with Mild Gestational Diabetes Mellitus. J. Clin. Endocrinol. Metab. 84: 1695-1699 [Abstract] [Full Text]  
• Story, M., Evans, M., Fabsitz, R. R, Clay, T. E, Rock, B. H., Broussard, B. (1999). The epidemic of obesity in American Indian communities and the need for childhood obesity-prevention programs. Am. J. Clin. Nutr. 69 : 747S-754S [Abstract] [Full Text]  
• Jequier, E., Tappy, L. (1999). Regulation of Body Weight in Humans. Physiol. Rev. 79: 451-480 [Abstract] [Full Text]  
• Fogelholm, M., Valve, R., Kukkonen-Harjula, K., Nenonen, A., Hakkarainen, V., Laakso, M., Uusitupa, M. (1998). Additive Effects of the Mutations in the {beta}3-Adrenergic Receptor and Uncoupling Protein-1 Genes on Weight Loss and Weight Maintenance in Finnish Women. J. Clin. Endocrinol. Metab. 83: 4246-4250 [Abstract] [Full Text]  
• GarcÍa-Rubi, E., Starling, R. D., Tchernof, A., Matthews, D. E., Walston, J. D., Shuldiner, A. R., Silver, K., Poehlman, E. T., Calles-Escandón, J. (1998). Trp64Arg Variant of the {beta}3-Adrenoceptor and Insulin Resistance in Obese Postmenopausal Women. J. Clin. Endocrinol. Metab. 83: 4002-4005 [Abstract] [Full Text]  
• Büettner, R., Schäffler, A., Arndt, H., Rogler, G., Nusser, J., Zietz, B., Enger, I., Hügl, S., Cuk, A., Schölmerich, J., Palitzsch, K.-D. (1998). The Trp64Arg Polymorphism of the {beta} 3-Adrenergic Receptor Gene Is Not Associated with Obesity or Type 2 Diabetes Mellitus in a Large Population-Based Caucasian Cohort. J. Clin. Endocrinol. Metab. 83: 2892-2897 [Abstract] [Full Text]  
• Fujisawa, T., Ikegami, H., Kawaguchi, Y., Ogihara, T. (1998). Meta-Analysis of the Association of Trp64Arg Polymorphism of {beta}3-Adrenergic Receptor Gene with Body Mass Index. J. Clin. Endocrinol. Metab. 83: 2441-2444 [Abstract] [Full Text]  
• Silver, K., Walston, J., Plotnick, L., Taylor, S. I., Kahn, C. R., Shuldiner, A. R. (1997). Molecular Scanning of {beta}-3-Adrenergic Receptor Gene in Total Congenital Lipoatrophic Diabetes Mellitus. J. Clin. Endocrinol. Metab. 82: 3395-3398 [Abstract] [Full Text]  
• Elbein, S. C. (1997). The Genetics of Human Noninsulin-Dependent (Type 2) Diabetes Mellitus. J. Nutr. 127: 1891-1891 [Abstract] [Full Text]  
• Nagase, T., Aoki, A., Yamamoto, M., Yasuda, H., Kado, S., Nishikawa, M., Kugai, N., Akatsu, T., Nagata, N. (1997). Lack of Association between the Trp64Arg Mutation in the {beta}3-Adrenergic Receptor Gene and Obesity in Japanese Men: A Longitudinal Analysis. J. Clin. Endocrinol. Metab. 82: 1284-1287 [Abstract] [Full Text]  
• Meyers, D. S., Skwish, S., Dickinson, K. E. J., Kienzle, B., Arbeeny, C. M. (1997). {beta}3-Adrenergic Receptor-Mediated Lipolysis and Oxygen Consumption in Brown Adipocytes from Cynomolgus Monkeys. J. Clin. Endocrinol. Metab. 82: 395-401 [Abstract] [Full Text]  
• Zilberfarb, V, Pietri-Rouxel, F, Jockers, R, Krief, S, Delouis, C, Issad, T, Strosberg, A. (1997). Human immortalized brown adipocytes express functional beta3-adrenoceptor coupled to lipolysis. J. Cell Sci. 110: 801-807 [Abstract]  
• Soloveva, V., Graves, R. A., Rasenick, M. M., Spiegelman, B. M., Ross, S. R. (1997). Transgenic Mice Overexpressing the {beta}1-Adrenergic Receptor in Adipose Tissue Are Resistant to Obesity. Mol. Endocrinol. 11: 27-38 [Abstract] [Full Text]  
• Jezek, P., Hanus, J., Semrad, C., Garlid, K. D. (1996). Photoactivated Azido Fatty Acid Irreversibly Inhibits Anion and Proton Transport through the Mitochondrial Uncoupling Protein. J. Biol. Chem. 271: 6199-6205 [Abstract] [Full Text]  
• Insel, P. A. (1996). Adrenergic Receptors -- Evolving Concepts and Clinical Implications. NEJM 334: 580-585 [Full Text]  
• Susulic, V. S., Frederich, R. C., Lawitts, J., Tozzo, E., Kahn, B. B., Harper, M.-E., Himms-Hagen, J., Flier, J. S., Lowell, B. B. (1995). Targeted Disruption of the beta(3)-Adrenergic Receptor Gene. J. Biol. Chem. 270: 29483-29492 [Abstract] [Full Text]  
• Widen, E., Lehto, M., Kanninen, T., Walston, J., Shuldiner, A. R., Groop, L. C. (1995). Association of a Polymorphism in the {beta}3-Adrenergic-Receptor Gene with Features of the Insulin Resistance Syndrome in Finns. NEJM 333: 348-352 [Abstract] [Full Text]  
• Clement, K., Vaisse, C., Manning, B. St. J., Basdevant, A., Guy-Grand, B., Ruiz, J., Silver, K. D., Shuldiner, A. R., Froguel, P., Strosberg, A. D. (1995). Genetic Variation in the {beta}3-Adrenergic Receptor and an Increased Capacity to Gain Weight in Patients with Morbid Obesity. NEJM 333: 352-354 [Abstract] [Full Text]  
• Arner, P. (1995). The {beta}3-Adrenergic Receptor -- A Cause and Cure of Obesity?. NEJM 333: 382-383 [Full Text]  
• Ranade, K., Chang, M.-S., Ting, C.-T., Pei, D., Hsiao, C.-F., Olivier, M., Pesich, R., Hebert, J., Chen, Y.-D. I., Dzau, V. J., Curb, D., Olshen, R., Risch, N., Cox, D. R., Botstein, D. (2001). High-Throughput Genotyping with Single Nucleotide Polymorphisms. Genome Res 11: 1262-1268 [Abstract] [Full Text]